0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Frelii
Its shares trade under the ticker FRLI. It has been listed since 18 January 2005. In the fiscal year to 31 December 2018, it reported revenue of $35,945 and a net loss of $5.5m. At that date it held total assets of $434,669 and shareholders' equity of $229,385.
Frélii, Inc. provides consumer affordable access to personalized health assessments and nutrition plans based on genetic data, physiology, environmental and lifestyle factors, and lab diagnostics all on one convenient web platform. The company is headquartered in Lehi, Utah. The company went IPO on 2005-01-18. The firm provides users personalized, deoxyribonucleic acid (DNA)-based diet and nutrition plans and identifies users’ health risks. Users can upload their raw genetic data by logging into their 23andMe profile and the Company’s site uploads that data for use by its artificial intelligence (AI)-based algorithm. Its products include KDIR, EZV-200, BLDB Tonic, Keotone-CoCoa and CTV. The firm provides tools, which includes personalized cookbook, meal planning, shopping lists, supplement packages and video workouts. The company provides Navii, which is computer learning-based algorithm generates insight about individual genetic health risks, and assists health providers to identify and treat various health concerns. Its wellness plans feature nutrition and fitness plans, supplement recommendations, downloadable menus, recipes, and shopping lists, and virtual personal training.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Technology
- Listed since
- 18 Jan 2005
- Employees
- 2
- Website
- frelii.com ↗
Leadership
Pay as last reported
- Mr. Ian JenkinsChief Executive Officer, Chief Financial Officer, Director, since 2017
- Mr. Sandeep UppalChief Administrative Officer
- Dr. Hans JenkinsDirector, Chief Medical Officer
- Ms. Leslie NorrisDirector, since 2018
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Frelii Inc possesses various strengths that contribute to its competitive advantage in the market. One of the key strengths is its advanced technology platform, which incorporates artificial intelligence and machine learning algorithms. This enables the company to efficiently analyze and interpret large amounts of genetic data, providing valuable insights to its clients.
- Another strength is Frelii's extensive network of partnerships and collaborations with renowned research institutions and genetic testing laboratories. By leveraging these relationships, Frelii gains access to diverse genetic data sets and expertise, enhancing the accuracy and reliability of its genetic analysis services.
- Additionally, the company benefits from a highly experienced and knowledgeable team of scientists, researchers, and geneticists. Their expertise in genomics and data analysis allows Frelii to continually improve and innovate in its field, staying ahead of competitors.
Weaknesses
- Despite its strengths, Frelii Inc also faces certain weaknesses that can hinder its growth and market position. One weakness is the reliance on external partnerships for access to genetic data. This dependency may limit the company's control over data availability and introduce potential delays or complications in data acquisition, affecting service delivery timelines.
- Another weakness is the high initial cost associated with implementing Frelii's technology platform and infrastructure. This can discourage some potential clients, particularly smaller research institutions or healthcare providers with limited budgets, from adopting Frelii's genetic analysis services.
- Furthermore, the complex nature of genomic analysis and interpretation may also pose a challenge as it requires highly specialized knowledge. Frelii needs to ensure that its platform is user-friendly and provides comprehensive support and training to its clients to overcome this weakness effectively.
Opportunities
- Frelii Inc operates in an industry that offers several potential opportunities for growth and market expansion. One significant opportunity is the increasing demand for personalized medicine and precision healthcare. As genomics becomes more integrated into healthcare, Frelii can capitalize on this trend by providing genetic analysis services that help tailor treatment plans and preventive measures to individual patients.
- Moreover, the expanding global market for genetic testing and analysis presents an opportunity for Frelii to penetrate new geographical regions and target diverse customer segments. By adapting its technology to different markets and complying with local regulations, the company can expand its customer base and revenue streams.
- Additionally, collaborations with pharmaceutical companies and biotech firms could open doors for Frelii to participate in cutting-edge research and development projects. Such partnerships can lead to the identification of novel biomarkers, the advancement of genomic therapies, and the discovery of new drug targets.
Threats
- Frelii Inc faces several threats that could impact its business operations and market position. One of the threats is the presence of well-established competitors in the genomics industry. These competitors often have brand recognition, extensive resources, and established customer relationships, posing a barrier to entry for new players like Frelii.
- Additionally, the evolving regulatory landscape surrounding genomic data privacy and protection presents a threat to Frelii's operations. Compliance with varying regulations in different jurisdictions requires significant resources and expertise. Failure to comply adequately may result in legal and reputational consequences for the company.
- Lastly, the potential emergence of alternative technologies or scientific breakthroughs in genomics could render Frelii's current offerings obsolete or less competitive. Continuous investment in research and development is crucial for adapting to changing market dynamics and staying at the forefront of innovation.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.